CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
CAMBRIDGE, Mass., Sep 04, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. EDT and at the Morgan Stanley Global Healthcare Unplugged
CAMBRIDGE, Mass., Aug 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Thomas Weisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 at 8:00 a.m. EDT.
First HCV protease inhibitor in pivotal trial for this difficult<br> to treat patient population<br><br> Trial to enroll all major treatment-failure patient groups,<br> including null responders, partial responders and relapsers<br><br> Two telaprevir registration programs to address significant unmet<br> need in treatment-naive and treatment-failure patients
CAMBRIDGE, Mass., Aug 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday, August 13, 2008 at 8:30 a.m. EDT.
CAMBRIDGE, Mass., Aug 05, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference on Wednesday, August 6, 2008 at 9:00 a.m. EDT.
-- Treatment-failure data and treatment-naive data strengthen<br> telaprevir's potential profile and highlight broad opportunity<br> in treatment of chronic hepatitis C virus (HCV) infection<br><br> -- VX-770, for cystic fibrosis (CF), completes enrollment for<br> 28-day Phase 2a study; 2009 targeted for initiation of<br> registration studies, pending 28-day study results
CAMBRIDGE, Mass., Jul 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has
Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&D efforts to support new Huntington's disease
